Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure

Prostate Cancer and Prostatic Diseases volume 12, pages 233–240 (2009)Cite this article

Abstract

Apart from the well-established adverse musculoskeletal and sexual health effects of androgen deprivation therapy (ADT), evidence is accumulating of substantial ADT-related cardiovascular and metabolic complications, which may impact quality of life and overall survival. In this brief review we discuss (1) the incidence of cardiovascular and metabolic complications during/following ADT from large cohort studies, (2) the increased risk factors for cardiovascular and metabolic disease from cross-sectional and prospective studies and (3) the use of physical exercise as a countermeasure in this new era of ADT-related toxicity. It is clear that exercise has the potential to provide a myriad of benefits to men undergoing ADT that may result in reduced morbidity and mortality, and subsequently improve quality of life.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS . Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615–1624.

    Article  CAS  PubMed  Google Scholar 

  2. Sharifi N, Gulley JL, Dahut WL . Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238–244.

    Article  CAS  PubMed  Google Scholar 

  3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS . Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–164.

    Article  CAS  PubMed  Google Scholar 

  4. Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 1083–1092.

    Article  CAS  PubMed  Google Scholar 

  5. Keating NL, O'Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448–4456.

    Article  CAS  PubMed  Google Scholar 

  6. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR . Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516–1524.

    Article  PubMed  Google Scholar 

  7. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS . Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493–1500.

    Article  CAS  PubMed  Google Scholar 

  8. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420–2425.

    Article  CAS  PubMed  Google Scholar 

  9. Smith MR, Lee H, Nathan DM . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305–1308.

    Article  CAS  PubMed  Google Scholar 

  10. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C . Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195–201.

    Article  CAS  Google Scholar 

  11. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.

    Article  CAS  PubMed  Google Scholar 

  12. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S . Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494–498.

    Article  CAS  PubMed  Google Scholar 

  13. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979–3983.

    Article  PubMed  Google Scholar 

  14. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS . Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581–588.

    CAS  PubMed  Google Scholar 

  15. Bong GW, Clarke Jr HS, Hancock WC, Keane TE . Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 2008; 71: 1177–1180.

    Article  PubMed  Google Scholar 

  16. Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 2006; 66: 439–444.

    Article  CAS  PubMed  Google Scholar 

  17. Helmrich SP, Ragland DR, Leung RW, Paffenbarger Jr RS . Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325: 147–152.

    Article  CAS  PubMed  Google Scholar 

  18. Helmrich SP, Ragland DR, Paffenbarger Jr RS . Prevention of non-insulin-dependent diabetes mellitus with physical activity. Med Sci Sports Exerc 1994; 26: 824–830.

    Article  CAS  PubMed  Google Scholar 

  19. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841–850.

    Article  CAS  PubMed  Google Scholar 

  20. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27: 92–99.

    Article  PubMed  Google Scholar 

  21. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008; 54: 816–823.

    Article  CAS  PubMed  Google Scholar 

  22. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188–2194.

    Article  CAS  PubMed  Google Scholar 

  23. Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44–47.

    Article  PubMed  Google Scholar 

  24. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261–4267.

    Article  CAS  PubMed  Google Scholar 

  25. Smith MR . Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742–745.

    Article  PubMed  Google Scholar 

  26. Lee H, McGovern K, Finkelstein JS, Smith MR . Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 1633–1637.

    Article  CAS  PubMed  Google Scholar 

  27. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM . Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410–6417.

    Article  CAS  PubMed  Google Scholar 

  28. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL . Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002; 95: 2136–2144.

    Article  PubMed  Google Scholar 

  29. Smith MR, Lee H, Fallon MA, Nathan DM . Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71: 318–322.

    Article  PubMed  Google Scholar 

  30. Suzuki K, Nukui A, Hara Y, Morita T . Glucose intolerance during hormonal therapy for prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 384–387.

    Article  CAS  PubMed  Google Scholar 

  31. Dockery F, Bulpitt CJ, Agarwal S, Rajkumar C . Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness. Aging Male 2002; 5: 216–222.

    Article  CAS  PubMed  Google Scholar 

  32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

    Article  Google Scholar 

  33. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS . Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med 1988; 319: 1379–1384.

    Article  CAS  PubMed  Google Scholar 

  34. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE . Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346: 793–801.

    Article  PubMed  Google Scholar 

  35. Rogers MA . Acute effects of exercise on glucose tolerance in non-insulin-dependent diabetes. Med Sci Sports Exerc 1989; 21: 362–368.

    Article  CAS  PubMed  Google Scholar 

  36. Trovati M, Carta Q, Cavalot F, Vitali S, Banaudi C, Lucchina PG et al. Influence of physical training on blood glucose control, glucose tolerance, insulin secretion, and insulin action in non-insulin-dependent diabetic patients. Diabetes Care 1984; 7: 416–420.

    Article  CAS  PubMed  Google Scholar 

  37. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl III HW, Blair SN . Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 1999; 281: 327–334.

    Article  CAS  PubMed  Google Scholar 

  38. Berg A, Halle M, Franz I, Keul J . Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Eur J Med Res 1997; 2: 259–264.

    CAS  PubMed  Google Scholar 

  39. Paffenbarger RS, Hale WE . Work activity and coronary heart mortality. N Engl J Med 1975; 292: 545–550.

    Article  CAS  PubMed  Google Scholar 

  40. Wannamethee SG, Shaper AG, Walker M . Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998; 351: 1603–1608.

    Article  CAS  PubMed  Google Scholar 

  41. Lee IM, Sesso HD, Paffenbarger Jr RS . Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk? Circulation 2000; 102: 981–986.

    Article  CAS  PubMed  Google Scholar 

  42. Lee IM, Paffenbarger Jr RS . Associations of light, moderate, and vigorous intensity physical activity with longevity. The Harvard Alumni Health Study. Am J Epidemiol 2000; 151: 293–299.

    Article  CAS  PubMed  Google Scholar 

  43. Sesso HD, Paffenbarger Jr RS, Lee IM . Physical activity and coronary heart disease in men: the Harvard Alumni Health Study. Circulation 2000; 102: 975–980.

    Article  CAS  PubMed  Google Scholar 

  44. Ruiz JR, Sui X, Lobelo F, Morrow Jr JR, Jackson AW, Sjostrom M et al. Association between muscular strength and mortality in men: prospective cohort study. BMJ 2008; 337: a439.

    Article  PubMed  Google Scholar 

  45. Jurca R, Lamonte MJ, Barlow CE, Kampert JB, Church TS, Blair SN . Association of muscular strength with incidence of metabolic syndrome in men. Med Sci Sports Exerc 2005; 37: 1849–1855.

    Article  PubMed  Google Scholar 

  46. Jurca R, Lamonte MJ, Church TS, Earnest CP, Fitzgerald SJ, Barlow CE et al. Associations of muscle strength and fitness with metabolic syndrome in men. Med Sci Sports Exerc 2004; 36: 1301–1307.

    Article  PubMed  Google Scholar 

  47. Taaffe DR, Pruitt L, Pyka G, Guido D, Marcus R . Comparative effects of high- and low-intensity resistance training on thigh muscle strength, fiber area, and tissue composition in elderly women. Clin Physiol 1996; 16: 381–392.

    Article  CAS  PubMed  Google Scholar 

  48. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ . High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 1990; 263: 3029–3034.

    Article  CAS  PubMed  Google Scholar 

  49. Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin BA et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007; 116: 572–584.

    Article  PubMed  Google Scholar 

  50. Galvão DA, Taaffe DR, Spry N, Newton RU . Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 340–346.

    Article  PubMed  Google Scholar 

  51. McCartney N . Role of resistance training in heart disease. Med Sci Sports Exerc 1998; 30: S396–S402.

    Article  CAS  PubMed  Google Scholar 

  52. Willey KA, Singh MA . Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights. Diabetes Care 2003; 26: 1580–1588.

    Article  PubMed  Google Scholar 

  53. Albright A, Franz M, Hornsby G, Kriska A, Marrero D, Ullrich I et al. American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc 2000; 32: 1345–1360.

    Article  CAS  PubMed  Google Scholar 

  54. American College of Sports Medicine Position stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 1998; 30: 975–991.

  55. Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B et al. AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine. Circulation 2000; 101: 828–833.

    Article  CAS  PubMed  Google Scholar 

  56. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21: 1653–1659.

    Article  PubMed  Google Scholar 

  57. Galvão DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K et al. Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 2008; 11: 160–165.

    Article  PubMed  Google Scholar 

  58. Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006; 38: 2045–2052.

    Article  PubMed  Google Scholar 

  59. Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006; 295: 2018–2026.

    Article  CAS  PubMed  Google Scholar 

  60. Simonsick EM, Montgomery PS, Newman AB, Bauer DC, Harris T . Measuring fitness in healthy older adults: the Health ABC Long Distance Corridor Walk. J Am Geriatr Soc 2001; 49: 1544–1548.

    Article  CAS  PubMed  Google Scholar 

  61. Simonsick EM, Fan E, Fleg JL . Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc 2006; 54: 127–132.

    Article  PubMed  Google Scholar 

  62. Hydock DS, Wonders KY, Schneider CM, Hayward R . Androgen deprivation therapy and cardiac function: effects of endurance training. Prostate Cancer Prostatic Dis 2006; 9: 392–398.

    Article  CAS  PubMed  Google Scholar 

  63. Galvão DA, Newton RU, Taaffe DR, Spry N . Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol 2008; 5: 306–307.

    Article  PubMed  Google Scholar 

  64. Kelemen MH, Effron MB, Valenti SA, Stewart KJ . Exercise training combined with antihypertensive drug therapy. Effects on lipids, blood pressure, and left ventricular mass. JAMA 1990; 263: 2766–2771.

    Article  CAS  PubMed  Google Scholar 

  65. Taaffe DR, Galvao DA, Sharman JE, Coombes JS . Reduced central blood pressure in older adults following progressive resistance training. J Hum Hypertens 2007; 21: 96–98.

    Article  CAS  PubMed  Google Scholar 

  66. Galvão DA, Newton RU . Review of exercise intervention studies in cancer patients. J Clin Oncol 2005; 23: 899–909.

    Article  PubMed  Google Scholar 

  67. Courneya KS . Exercise in cancer survivors: an overview of research. Med Sci Sports Exerc 2003; 35: 1846–1852.

    Article  PubMed  Google Scholar 

  68. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779–786.

    Article  CAS  Google Scholar 

  69. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787–2791.

    CAS  PubMed  Google Scholar 

  70. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K . The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 657–660.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Cancer Council of Western Australia, Cancer Council of Queensland and Prostate Cancer Foundation of Australia.

Author information

Authors and Affiliations

  1. Vario Health Institute, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia

    D A Galvão & R U Newton

  2. School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia

    D R Taaffe

  3. Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western A, ustralia, Australia

    N Spry & D Joseph

  4. Faculty of Medicine, University of Western Australia, Nedlands, Western A, ustralia, Australia

    N Spry & D Joseph

Authors
  1. D A Galvão
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D R Taaffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Spry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Joseph
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R U Newton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D A Galvão.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galvão, D., Taaffe, D., Spry, N. et al. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12, 233–240 (2009). https://doi.org/10.1038/pcan.2009.12

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.12

Keywords

This article is cited by

Search

Advanced search

Quick links